Metastatic breast ductal carcinoma detected in a toremifene-associated endometrial polyp: case report and literature review

Uterine metastases are rare events, but when they occur, the first extragenital neoplasm responsible is breast carcinoma. Toremifene, used in breast cancer hormonotherapy, has a partial estrogenic agonist effect in the endometrium, responsible for potential abnormalities, like polyps. A 53-year-old...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological surgery 2010-02, Vol.7 (1), p.19-21
Main Authors: Rodrigues, Marta, Batista, Sandra, Ramalho, Graça, Dias, Enrique
Format: Article
Language:English
Subjects:
Breast cancer
Communication
Gynecology
Interventional Radiology
Medical research
Medicine
Medicine & Public Health
Minimally Invasive Surgery
Obstetrics/Perinatology/Midwifery
Reproductive Medicine
Surgical Oncology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Uterine metastases are rare events, but when they occur, the first extragenital neoplasm responsible is breast carcinoma. Toremifene, used in breast cancer hormonotherapy, has a partial estrogenic agonist effect in the endometrium, responsible for potential abnormalities, like polyps. A 53-year-old woman, receiving toremifene due to previously excised breast ductal carcinoma, presented with endometrial thickness during an abdominopelvic ultrasound follow-up. Hysteroscopy revealed an endometrial polyp, which was removed. Microscopic examination showed infiltration by a malignant ductal pattern neoplasm, with signet ring cells. The patient underwent hysterectomy and bilateral salpingo-oophorectomy. The final pathological diagnosis was metastatic breast carcinoma to the endometrium and cervix. This is the first reported case of breast metastases detected in a toremifene-associated endometrial polyp.
ISSN:1613-2076
1613-2084
DOI:10.1007/s10397-008-0457-z